PCN136 Cost-Effectiveness Analysis of Dacomitinib Versus Gefitinib for the First-line Treatment of Locally Advanced or Metastatic Non-Small Cell Lung Cancer with Epidermal Growth Factor Receptor (EGFR)-Activating Mutations in Portugal
Abstract
Authors
L. Silva Miguel A.T. Paquete J. Alarcão R. Guerreiro M. Inês M. Borges